One Of The Cyclos Is A 1,2-thiazine (e.g.,1,2-benzothiazines, Etc.) Patents (Class 514/226.5)
-
Publication number: 20100203145Abstract: The invention concerns a process for the continuous treatment of an emulsion and/or a micro-emulsion assisted by an “expanded liquid” for the production of micro- and/or nano-particles or micro- and/or nano-spheres containing one or more active ingredients. In particular, a liquid solvent expanded by compressed or supercritical CO2 is contacted with an O/W emulsion, or alternatively a W/O emulsion or multiple emulsions, formed by an external phase that is itself a liquid expanded by compressed CO2. The expanded liquid forms a solution with the dispersed phase of the emulsion and extracts it inducing the formation of the desired particles of the dissolved compounds. The process is carried out in a counter-current packed column wherein the expanded emulsion is fed from the top, while the expanded liquid is fed from the bottom. Thanks to the presence of the expanded liquid, any deposition of the solid particles produced on the packing elements is avoided, thus preventing any column blockage.Type: ApplicationFiled: July 25, 2008Publication date: August 12, 2010Applicant: UNIVERSITA' DEGLI STUDI DI SALERNOInventors: Ernesto Reverchon, Giovanna Della Porta
-
Publication number: 20100203103Abstract: The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.Type: ApplicationFiled: August 15, 2008Publication date: August 12, 2010Inventors: Reza Dana, Mohammad Dastjerdi
-
Patent number: 7767665Abstract: This invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.Type: GrantFiled: April 8, 2008Date of Patent: August 3, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Yutaka Nakayama, Akira Kawada, Haruhide Kimura, Taisuke Tawaraishi
-
Publication number: 20100183607Abstract: Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.Type: ApplicationFiled: March 23, 2010Publication date: July 22, 2010Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Stanley L. Hazen, Michael Kinter, Marc S. Penn, Jonathan Smith, Lemin Zheng
-
Publication number: 20100178349Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.Type: ApplicationFiled: June 3, 2008Publication date: July 15, 2010Applicant: BASF SEInventors: Karl Kolter, Michael Schönherr, Silke Gebert, Kathrin Meyer-Böhm, Angelika Maschke
-
Publication number: 20100173872Abstract: A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.Type: ApplicationFiled: January 4, 2010Publication date: July 8, 2010Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Anil Gulati
-
Publication number: 20100173876Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.Type: ApplicationFiled: July 30, 2009Publication date: July 8, 2010Applicant: The Board of Regents of the University of Texas SystemInventors: Lenard M. Lichtenberger, Shiqiang Tian
-
Publication number: 20100166856Abstract: The invention relates to a modified release pharmaceutical composition in capsules with coated microspheres, combining two active ingredients with radically different plasma concentration times, namely a muscle relaxant (tizanidine) and a non-steroidal anti-inflammatory drug (meloxicam), and pharmaceutically acceptable excipients or vehicles; as well as a method for producing the composition and the use of said combination for the preparation of a drug having synergic therapeutic effect in the treatment of spasticity, disorders related to the skeletal muscle and/or muscular ailments, and moderate to severe pain in general.Type: ApplicationFiled: October 16, 2007Publication date: July 1, 2010Applicant: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Enrique Raúl Garcia-Salgado Lopez, Angélica Arzola Paniagua, Luis Fernando Poot López, Francisco Escorcia Rodríguez, Gustavo Barranco Hernandez
-
Publication number: 20100158993Abstract: Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae.Type: ApplicationFiled: December 21, 2009Publication date: June 24, 2010Applicant: ISW Group, Inc.Inventors: Monique Spann-Wade, Anthony Ward
-
Publication number: 20100152173Abstract: The present invention relates to a tablet comprising at least a first and second active, the first active being in the form of a non-aqueous granulate, the second active ingredient being in the form of melt extrudated granules or a granulate (aqueous or non-aqueous). The first and second active forms are blended together. The present invention is further directed to a method of producing said tablet.Type: ApplicationFiled: March 19, 2008Publication date: June 17, 2010Inventors: Huw Jones, Gurmeet Rajput
-
Publication number: 20100144719Abstract: The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate/polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well.Type: ApplicationFiled: December 3, 2009Publication date: June 10, 2010Inventor: Bhagwati P. Kabra
-
Publication number: 20100144591Abstract: The present invention relates to compounds of formula (I); compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IGT) in a patient.Type: ApplicationFiled: February 27, 2008Publication date: June 10, 2010Inventors: Robert G. Aslanian, Jean E. Lachowicz, Michael Y. Berlin, Joyce J. Hwa
-
Publication number: 20100135984Abstract: Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.Type: ApplicationFiled: December 2, 2008Publication date: June 3, 2010Inventors: Roderick A. Hyde, Stephen L. Malaska, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20100137292Abstract: This invention is a novel pharmaceutical formulation of aqueous EDTA (Ethylene diamine tetraacetic acid) free solution of meloxicam in combination with meglumin for administration by oral or parenteral route, comprising one or more pharmaceutically acceptable excipients which is comprising N,N dimethylacetamide and propylene glycol for treating mammals, preferably animals.Type: ApplicationFiled: November 30, 2009Publication date: June 3, 2010Applicant: SANOVEL ILAC SANAYI VE TICARET A.S.Inventors: Hasan Ali Turp, Ali Türkyilmaz, Cevdet Akdogan
-
Publication number: 20100137246Abstract: Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.Type: ApplicationFiled: December 2, 2008Publication date: June 3, 2010Inventors: Roderick A. Hyde, Stephen L. Malaska, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20100129366Abstract: The present invention relates to new thiazole inhibitors of cyclooxygenase, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 19, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manouchehr Shahbaz
-
Publication number: 20100125067Abstract: The present invention relates to new sulfonamide inhibitors of carbonic anhydrase II, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 19, 2009Publication date: May 20, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100119508Abstract: The present invention relates to new phenylacetic acid inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 11, 2009Publication date: May 13, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucherhr M. Shahbaz
-
Publication number: 20100112048Abstract: The present invention relates to a synergistic combination for preventing the onset and/or progression of dementia or Alzheimer's disease in individuals at increased risk thereof for example because of family history, genetic factors, and/or environmental factors. This combination comprises synergistically effective amounts of vitamin C, vitamin E, DHA and at least one NSAID such as ibuprofen.Type: ApplicationFiled: July 19, 2006Publication date: May 6, 2010Inventor: Majid Fotuhi
-
Publication number: 20100113396Abstract: Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans.Type: ApplicationFiled: November 3, 2009Publication date: May 6, 2010Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Anil Gulati
-
Publication number: 20100093711Abstract: The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase, and/or 11beta-hydroxylase (CYP11B1), and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase and/or CYP11B1. Finally, the present invention also provides a pharmaceutical composition.Type: ApplicationFiled: December 14, 2007Publication date: April 15, 2010Inventors: Qi-Ying Hu, Gary Michael Ksander
-
Publication number: 20100093712Abstract: The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimen.Type: ApplicationFiled: October 1, 2009Publication date: April 15, 2010Applicant: Applied Pharmacy Services, Inc.Inventors: Alton Samuel Kelley, II, James Gregory Sullivan
-
Publication number: 20100087402Abstract: The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Applicant: Vivus, Inc.Inventors: Changjin Wang, Leland F. Wilson
-
Publication number: 20100081652Abstract: Disclosed is an extracellular matrix genetranscription inhibitor composition or the like characterized by containing a cinnamoyl compound represented by the formula (I) below: and an inert carrier.Type: ApplicationFiled: March 2, 2006Publication date: April 1, 2010Inventors: Hiroaki Shiraki, Kiyoshi Higashi, Yoshitaka Tomigahara, Junya Takahashi
-
Publication number: 20100081610Abstract: The present invention relates to ?-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure ?-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.Type: ApplicationFiled: August 21, 2007Publication date: April 1, 2010Inventors: Viswajanani J. Sattigeri, Venkata P. Palle, Manoj Kumar Khera, Ranaheer Reddy, Manoj Kumar Tiwari, Ajay Soni, Abdul Rehman Abdul Rauf, Sony Joseph, Arpita Musib, Sunanda G. Dastidar, Punit Kumar Srivastava
-
Publication number: 20100081631Abstract: Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, a gastric ulcer, non-steroidal anti-inflammatory drug-induced gastroenteropathy and intestinal ischemia. Such administration results in treating or preventing the disease or condition.Type: ApplicationFiled: December 11, 2007Publication date: April 1, 2010Inventors: Guang Liang Jiang, Wha Bin Im, Larry A. Wheeler
-
Publication number: 20100063035Abstract: Nitroderivatives of dorzolamide and brinzolamide having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies.Type: ApplicationFiled: December 3, 2007Publication date: March 11, 2010Applicant: Nicox S.A.Inventors: Francesca Benedini, Stefano Biondi, Ennio Ongini
-
Publication number: 20100048518Abstract: The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.Type: ApplicationFiled: October 27, 2009Publication date: February 25, 2010Applicants: Sidem Pharma, Mitsubishi Pharma CorporationInventors: Francois Schutze, Suzy Charbit, Hervé Ficheux, Michel Homerin, Alain Taccoen, Nathalie Taccoen, Yoshio Inaba
-
Patent number: 7666863Abstract: The present invention relates to benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.Type: GrantFiled: May 24, 2007Date of Patent: February 23, 2010Assignees: ViroPharma Incorporated, WYETHInventors: Ashis K. Saha, Christopher J Burns, Alfred M. Del Vecchio, Thomas R. Bailey, Jason A. Reinhardt, Bheemashankar A. Kulkarni, Thomas H. Faitg, Hao Feng, Susan R. Rippin, Charles W. Blackledge, David J. Rys, Thomas A. Lessen, John Swestock, Yijun Deng, Theodore J. Nitz
-
Publication number: 20100035848Abstract: A method for managing or treating an inflammatory, erosive, dyspeptic or reflux disorder of the proximal digestive tract of a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor. A therapeutic combination, useful to treat any disease or condition in which an NSAID is indicated, comprises an NSAID in an anti-inflammatory, analgesic or antipyretic effective amount and a gastroprotective agent that comprises an ACE2 inhibitor in an amount effective to protect mucosal surfaces of the proximal digestive tract from erosion or ulceration induced by the NSAID.Type: ApplicationFiled: March 10, 2009Publication date: February 11, 2010Inventors: Stephen Richard Donahue, Michael David Jacobson, John Joseph Byrnes, III, Luz-Maria Guzman, Thomas Michael Barnes, Robert Mark Coopersmith, Scott Edward Malstrom
-
Publication number: 20100035868Abstract: A method of treating or preventing a pathological condition of the uterus in an individual the method comprising administering to the individual any one or more of an inhibitor of cyclooxygenase-2 (COX-2), an inhibitor of prostaglandin E synthase (PGES), or an EP2 or EP4 receptor antagonist. Typically, the pathological condition is uterine cancer, fibroids or endometriosis.Type: ApplicationFiled: October 6, 2009Publication date: February 11, 2010Applicant: MEDICAL RESEARCH COUNCILInventor: Henry Nicolas Jabbour
-
Patent number: 7659267Abstract: As prophylactic and/or therapeutic agents for cardiovascular diseases, bone or joint diseases, infectious diseases, inflammatory diseases, kidney diseases, etc. having safe and excellent effects of cell death inhibition, MIF binding, etc., there are provided compounds represented by formula: [wherein, R1 represents a halogen atom, etc., R2 represents a group represented by formula: (wherein, R3 represents hydrogen atom, an optionally substituted alkoxy, etc., R4 represents hydrogen atom, bromine atom, cyano, etc., R5 represents hydrogen atom, hydroxy, etc., R6 represents hydrogen atom, etc., R7 represents hydrogen atom, etc.) etc., and n represents an integer of 0 to 4] or salts thereof.Type: GrantFiled: December 4, 2003Date of Patent: February 9, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Yutaka Nakayama, Haruhide Kimura
-
Publication number: 20100029599Abstract: The present invention relates to indolylamide derivatives of the general formula (I), to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP2 receptor.Type: ApplicationFiled: July 29, 2009Publication date: February 4, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Marcus Koppitz, Antonius Ter Laak, Tim Wintermantel, Bernhard Lindenthal, Nico Bräuer, Gernot Langer, Bernd Buchmann
-
Publication number: 20100016285Abstract: The blow-described formula (I) [Ch.Type: ApplicationFiled: July 23, 2009Publication date: January 21, 2010Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hideharu UCHIDA, Shinichi OGAWA, Muneyoshi MAKABE, Yoshitaka MAEDA
-
Publication number: 20100009977Abstract: Disclosed herein is an improved process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide (Brinzolamide) and novel intermediates thereof.Type: ApplicationFiled: October 12, 2007Publication date: January 14, 2010Inventors: Dhananjay Govind Sathe, Radhakrishnan Venkatasubramanian Tarur, Nandu Baban Bhise, Ajit Bhaskar Shinde, Santosh Pardeshi
-
Publication number: 20100004200Abstract: Provided herein is a process for making compositions and methods of using such compositions to treat pain, inflammation and/or inflammatory disease or disorder including degenerative osteoarticular disease.Type: ApplicationFiled: July 2, 2009Publication date: January 7, 2010Applicant: Monte Verde S.A.Inventor: Jorge Daniel Nieto
-
Publication number: 20100004231Abstract: This application discloses 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-V: wherein, variables Q, R, Y1, Y2, Y2?, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.Type: ApplicationFiled: July 1, 2009Publication date: January 7, 2010Inventors: Nolan James Dewdney, Yan Lou, Eric Brian Sjogren, Michael Soth, Zachary Kevin Sweeney
-
Publication number: 20090325943Abstract: This invention relates to veterinary pharmaceutical compositions based on a combination of tramadol and meloxicam or carprofen for the treatment of pain and inflammation in animals.Type: ApplicationFiled: May 14, 2007Publication date: December 31, 2009Inventors: Andrea Formenti, Filippo Formenti
-
Publication number: 20090312706Abstract: Described herein are transdermal delivery devices composed of at least one resealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically.Type: ApplicationFiled: April 16, 2009Publication date: December 17, 2009Inventors: Totada Shantha, Jessica Shantha, Erica Shantha, Lauren Shantha
-
Publication number: 20090306058Abstract: Compounds of Formula (I) are disclosed for treatment of cancer.Type: ApplicationFiled: May 16, 2006Publication date: December 10, 2009Inventors: Huw David Lewis, Timothy Harrison, Mark Steven Shearman
-
Publication number: 20090280177Abstract: It is difficult to develop pharmaceutical agents for treating fibromyalgia since both the pathogenetic cause and the onset mechanism remain to be clarified. An antirheumatic agent salazosulfapyridine was administered to fibromyalgia patients. Unexpectedly, salazosulfapyridine was seen to be effective in fibromyalgia patients in whom neither the rheumatoid factor nor an immune disorder was detectable, in particular to relieve pain of enthesitis. Furthermore, salazosulfapyridine was also effective to alleviate enthesitis and to relieve pain in fibromyalgia. In addition, the combined use of salazosulfapyridine with a corticosteroid or a nonsteroidal anti-inflammatory agent potentiated the therapeutic effect of salazosulfapyridine in clinical patients to whom salazosulfapyridine alone was not effective enough.Type: ApplicationFiled: October 4, 2007Publication date: November 12, 2009Inventor: Kusuki Nishioka
-
Publication number: 20090281093Abstract: The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) that release hydrogen sulfide (H2S). The present invention also provides methods for treating, preventing and/or reducing inflammation-associated diseases by releasing H2S in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as infective diseases employing said compounds.Type: ApplicationFiled: July 29, 2005Publication date: November 12, 2009Applicant: C.T.G. PHARMA S.R.L.Inventors: Anna Sparatore, Piero Del Soldato
-
Publication number: 20090258856Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Type: ApplicationFiled: June 23, 2009Publication date: October 15, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias ECKHARDT, Norbert HAUEL, Elke LANGKOPF, Frank HIMMELSBACH, Iris KAUFFMANN-HEFNER, Mohammad TADAYYON, Michael MARK
-
Publication number: 20090246266Abstract: A composition for transdermal permeation and a preparation method are disclosed. The composition including meloxicam as an active ingredient and further including at least one permeation enhancing agent selected from the group consisting of a sorbitan fatty acid derivative, a polyglyceryl fatty acid derivative, a polyethylene glycol vegetable oil ester, a polyethylene glycol corn oil glyceride, and a polyethylene glycol almond oil glyceride and at least one acrylic polymer adhesive having a hydroxyl group or no functional group.Type: ApplicationFiled: September 20, 2007Publication date: October 1, 2009Applicant: GOLDEN PACIFIC BIO LIMITEDInventor: Hoo-Kyun Choi
-
Publication number: 20090239852Abstract: Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject.Type: ApplicationFiled: April 3, 2009Publication date: September 24, 2009Inventors: Dieter Binder, Eva Binder
-
Publication number: 20090221563Abstract: The present invention relates to an oral suspension comprising meloxicam, its preparation and its use in alleviating inflammation and pain in both acute and chronic musculo-skeletal disorders.Type: ApplicationFiled: December 2, 2005Publication date: September 3, 2009Inventors: Caspar Peter Elisabeth Biesmans, Bart De Spiegeleer
-
Publication number: 20090215757Abstract: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam.Type: ApplicationFiled: December 16, 2005Publication date: August 27, 2009Inventors: Tibor Mezei, Gyula Simig, Enikó Molnár, Gyula Lukács, Márta Porcs-Makkay, Balázs Volk, Valéria Hofmanné Fekete, Kálmán Nagy, Norbert Mesterházy, György Krasznai, Györgyi Vereczkeyné Donáth, Gyuláné Körtvélyessy, Éva Pécsi
-
Patent number: 7579389Abstract: An antimicrobial additive composition is provided which economically and efficiently imparts antimicrobial characteristics to acrylic polymers, and particularly thermoformable acrylic sheets made from such polymers. The antimicrobial composition comprises an alkyl dimethyl ammonium saccharinate, an oxathiazine, an azole, an isothiazoline, a chlorothalonil, and/or mixtures thereof, among others.Type: GrantFiled: August 26, 2004Date of Patent: August 25, 2009Assignee: Microban Products CompanyInventor: Ivan Wei-Kang Ong
-
Publication number: 20090203680Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.Type: ApplicationFiled: January 22, 2009Publication date: August 13, 2009Applicant: Thar PharmaceuticalsInventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
-
Publication number: 20090197874Abstract: A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof.Type: ApplicationFiled: June 11, 2007Publication date: August 6, 2009Applicant: ALPEX PHARMA SAInventors: Federico Stroppolo, Shahbaz Ardalan